Clinical Aspects, Cytogenetics and Disease Evolution in Myelodysplastic Syndromes

References

• Saarni M. I., Linman J. W. Preleukemia. The hematologic syndrome preceding acute leukemia. Am. J. Med. 1973; 55: 38–48
   PubMed Web of Science ®Google Scholar
• Bennett J. M., Catovsky D., Daniel M. T. Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 1982; 51: 189–199
   PubMed Web of Science ®Google Scholar
• Yoshida Y., Oguma S., Uchino H., Maekawa T. Refractory myelodysplastic aneamias with hypocellular bona marrow. J. Clin. Pathol. 1988; 41: 763–767
   PubMed Web of Science ®Google Scholar
• Nand S., Godwin J. E. Hypoplastic myelodysplastic syndrome. Cancer 1988; 62: 958–964
   PubMed Web of Science ®Google Scholar
• Toyama K., Ohyashiki K., Yoshida Y. Clinical and cytogenetic findings of myelodysplastic syndromes showing hypocellular bone marrow or minimal dysplasia, in comparison with typical myelodysplastic syndromes. Int. J. Hematol. 1993; 58: 53–61
   PubMed Web of Science ®Google Scholar
• Mascheck H., Kaloutsi V., Rodriguez-Kaiser M. Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis. Ann. Hematol. 1993; 66: 117–122
   PubMed Web of Science ®Google Scholar
• Ohyashiki K., Yokoyama K., Kimura Y. Myelodysplastic syndrome evolving into a myeloproliferative disorder: one disease or two?. Leukemia 1993; 7: 338–340
   PubMed Web of Science ®Google Scholar
• Michaux J. L., Martiat O. Chronic myelomonocytic leukaemia (CMML)—a myelodysplastic or myeloproliferative syndrome?. Leukemia Lym. 1993; 9: 35–41
   PubMed Web of Science ®Google Scholar
• Mufti G. J., Stevens J. R., Oscier D. G., Hamblin T. J., Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br. J. Haematol. 1984; 59: 425–433
   Web of Science ®Google Scholar
• Mufti G. J., Galton D. A. Myelodysplastic syndromes: natural history and features of prognostic importance. Clin. Haematol. 1986; 15: 953–971
   PubMedGoogle Scholar
• Koeffler H. P. Myelodysplastic syndromes (preleukemia). Sem. Hematol. 1986; 23: 284–299
   PubMed Web of Science ®Google Scholar
• Hamblin T. J., Oscier D. G. Myelodysplastic syndromes—A practical guide. Hematol. Oncol. 1987; 5: 19–34
   PubMed Web of Science ®Google Scholar
• Bartram C. R. Molecular genetic aspects of myelodysplastic syndromes. Hematol. Oncol. Clin. North Am. 1992; 6: 557–570
   PubMed Web of Science ®Google Scholar
• Culligan D. J., Jacobs A. Minimal diagnostic criteria for the myelodysplastic syndrome. Leukemia Res. 1992; 16: 4–5
   PubMed Web of Science ®Google Scholar
• Tricot G. J. Minimal diagnostic criteria for the myelodysplastic syndrome in clinical practice. Leukemia Res. 1992; 16: 5–6
   PubMed Web of Science ®Google Scholar
• Ost A., Reizenstein P. Minimal diagnostic criteria for the myelodysplastic syndrome. Leukemia Res. 1992; 16: 9–11
   PubMed Web of Science ®Google Scholar
• Yoshida Y., Stephensen J., Mufti G. J. Myelodysplastic syndrome from morphology to molecular biology. I. Classification, natural history and cell biology of myelodysplasia. Int. J. Haematol. 1993; 57: 87–97
   PubMed Web of Science ®Google Scholar
• Narayanan M. N., Geary C. G., Freemont A. J., Kendra J. R. Long-term follow-up of aplastic anaemia. Br. J. Haematol. 1994; 86: 837–847
   PubMed Web of Science ®Google Scholar
• Kojima S., Tsuchida M., Matsuyama T. Myelodysplasia and leukemia after treatment of aplastic anemia with G-CSF. New Engl. J. Med. 1992; 326: 1294–1295
   PubMed Web of Science ®Google Scholar
• Sultan C., Sigaux F., Imbert M. Acute myelodysplasia with myelofibrosis. A report of eight cases. Br. J. Haematol. 1981; 42: 9–20
   Web of Science ®Google Scholar
• Ohyashiki K., Sasao I., Ohyashiki J. H. Clinical and cytogenetic characteristics of myelodysplastic syndrome developing myelofibrosis. Cancer 1991; 68: 178–183
   PubMed Web of Science ®Google Scholar
• Paglica A., Layton D. M., Manoharan A. Myelofibrosis in primary myelodysplastic syndromes: a clinico-morphological study of 10 cases. Br. J. Haematol. 1989; 71: 499–504
   PubMed Web of Science ®Google Scholar
• Verhoef G. E., Van Den Berghe H., Boogaerts M. A. Myelodysplastic syndrome with bone marrow fibrosis: a myelodysplastic disorder with proliferative features. Ann. Hematol. 1991; 63: 235–241
   PubMed Web of Science ®Google Scholar
• Solomon E., Borrow J., Goddard A. D. Chromosome aberrations and cancer. Science 1991; 254, 1153-
   Web of Science ®Google Scholar
• Mitani K., Ogawa S., Tanaka T. Generation of the AML-1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J. 1994; 13: 504–510
   PubMed Web of Science ®Google Scholar
• Russell M., List A., Greenberg P. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. Blood 1994; 84: 1243–1248
   PubMed Web of Science ®Google Scholar
• Ohyashiki J. H., Ohyashiki K., Shimamoto T. Ecotropic virus integration site-1 gene preferentially expressed in post-myelodysplasia acute myeloid leukemia: Possible association with GATA-1, GATA-2 and stem cell leukemia gene expression. Blood 1995; 85: 3713–3718
   PubMed Web of Science ®Google Scholar
• Berkowicz M., Rosner E., Rechavi G. Atypical chronic myelomonocytic leukemia with eosinophilia and translocation (5;12) A new association?. Cancer Genet. Cytogenet. 1991; 51: 277–278
   PubMed Web of Science ®Google Scholar
• Golub T. R., Baker G. F., Lovett M., Gilliland D. G. Fusion of PDGF receptor b to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77: 307–316
   PubMed Web of Science ®Google Scholar
• Boulnood J., Fidler C. Chromosomal deletions in myelodysplasia. Leuk. Lymphoma 1995; 17: 71–78
   PubMed Web of Science ®Google Scholar
• Jacobs R. H., Cornbleet M. A., Vardiman J. W., Larson R. A., Le Beau M. M., Rowley J. D. Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood 1986; 67: 1765–1772
   PubMed Web of Science ®Google Scholar
• Billstrom R., Thiede T., Hansen S. A. Bone marrow karyotype and prognosis in primary myelodysplastic syndromes. Eur. J. Haematol. 1988; 41: 341–346
   PubMed Web of Science ®Google Scholar
• Horiike S., Taniwaki M., Misawa S., Abe T. Chromosome abnormalities and karyotypic evolution in 83 patients with myelodysplastic syndrome and predictive value for prognosis. Cancer 1988; 62: 1129–1138
   PubMed Web of Science ®Google Scholar
• Knapp R. H., Dewald G. W., Pierre R. V. Cytogenetic studies in 174 consecutive patients with preleukemic or myelodysplastic syndromes. Mayo Clin. Proc. 1985; 60: 507–516
   PubMed Web of Science ®Google Scholar
• Tricot G., Vlietinck R., Boogaerts M. A. Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy, and chromosomal analysis. Br. J. Haematol. 1985; 60: 19–32
   PubMed Web of Science ®Google Scholar
• Yunis J. J., Lobell M., Arnesen M. A. Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia. Br. J. Haematol. 1988; 68: 189–194
   PubMed Web of Science ®Google Scholar
• Musilova J., Michalova K. Chromosome study of 85 patients with myelodysplastic syndrome. Cancer Genet. Cytogenet. 1988; 33: 39–50
   PubMed Web of Science ®Google Scholar
• Suciu S., Kuse R., Weh H. J., Hossfeld D. K. Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome. Cancer Genet. Cytogenet. 1990; 44: 15–26
   PubMed Web of Science ®Google Scholar
• Geddes A. D., Bowen D. T., Jacobs A. Clonal karyotype abnormalities and clinical progression in the myelodysplastic syndrome. Br. J. Haematol. 1990; 76: 194–202
   PubMed Web of Science ®Google Scholar
• Ohyashiki K., Sasao I., Ohyashiki J. H. Cytogenetic and clinical findings of myelodysplastic syndromes with a poor prognosis, an experience with 97 cases. Cancer 1992; 70: 94–99
   PubMed Web of Science ®Google Scholar
• Pieer R. V., Catovsky D., Mufti G. J. Clinical-cytogenetic correlations in myelodysplasia (preleukemia). Cancer Genet. Cytogenet. 1989; 40: 149–161
   PubMed Web of Science ®Google Scholar
• Vila L., Charrin C., Archimbaud E. Correlations between cytogenetics and morphology in myelodysplastic syndromes. Blut 1990; 60: 223–227
   PubMedGoogle Scholar
• Bernasconi P., Alessandrino E. P., Boni M. Karyotype in myelodysplastic syndrome. Relation to morphology, clinical evolution, and survival. Am. J. Hematol. 1994; 46: 270–277
   PubMed Web of Science ®Google Scholar
• Parlier V., Van Melle G., Beris P. H. Hematologic, clinical, and cytogenetic analysis in 109 patients with primary myelodysplastic syndrome. Cancer Genet. Cytogenet. 1994; 78: 219–231
   PubMed Web of Science ®Google Scholar
• Sole F., Prieto F., Badia L. Cytogenetic studies in 112 cases of untreated myelodysplastic syndromes. Cancer Genet. Cytogenet. 1992; 64: 12–20
   PubMed Web of Science ®Google Scholar
• Noel A., Tefferi A., Pierre V., Jenkins R. B., Dewald G. W. Karyotypic analysis in primary myelodysplastic syndromes. Blood Rev. 1993; 7: 10–18
   PubMed Web of Science ®Google Scholar
• Haase D., Fonatsch C., Freund M. Cytogenetic findings in 179 patients with myelodysplastic syndromes. Ann. Hematol. 1995; 70: 171–178
   PubMed Web of Science ®Google Scholar
• Van Den Berghe H., Cassiman J. J., David G. The 5q-anomaly. Cancer Genet. Cytogenet. 1985; 17: 189–225
   PubMed Web of Science ®Google Scholar
• Le Beau M. M., Albain K. S., Larson R. A. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: Further evidence for characteristic abnormalities of chromosomes No. 5 and 7. J. Clin. Oncol. 1986; 4: 325–345
   PubMed Web of Science ®Google Scholar
• Toyama K., Ohyashiki K., Yoshida Y. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndrome: a multicentric study in Japan. Leukemia 1993; 7: 499–508
   PubMed Web of Science ®Google Scholar
• Willman C. L., Sever C. E., Pallavicini M. G. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 1933; 259: 968–971
   Web of Science ®Google Scholar
• Boultwood J., Fidler C., Lewis S. Allelic loss of IRF1 in myelodysplasia and acute leukemia: retention of IRF1 on the 5q-chromosome in some patients with the 5q- syndrome. Blood 1993; 89: 2611–2616
   Google Scholar
• Ohyashiki K., Iwabuchi A., Sasao I., Ohyashiki J. H., Ito H., Toyama K. Clinical and cytogenetic significance of myelodysplastic syndrome with disease evolution. Cancer Genet. Cytogenet 1993; 67: 71–79
   PubMed Web of Science ®Google Scholar
• Sanz G. F., Sanz M. A., Vallespi T., Del Canizo M. C. Two types of acquired idiopathic sideroblastic anaemia (AISA). Br. J. Haematol. 1990; 75: 633–634
   PubMed Web of Science ®Google Scholar
• Iwabuchi A., Ohyashiki K., Ohyashiki J. H. Percentage of bone marrow blasts and chromosomal changes in patients with refractory anemia help to determine prognoses. Int. J. Hematol. 1994; 60: 207–213
   PubMed Web of Science ®Google Scholar
• Mecucci C., Rege-Cambrin G., Michaux J. L., Mecucei C., Van Den Berghe H. Multiple chromosomally distinct cell populations in myelodysplastic syndromes and their possible significance in the evolution of the disease. Br. J. Haematol. 1986; 64: 699–706
   PubMed Web of Science ®Google Scholar
• Ohyashiki J. H., Ohyashiki K., Fujimura T. Telomere shortening associated with disease evolution patterns in myelodysplastic syndromes. Cancer Res. 1994; 54: 3557–3560
   PubMed Web of Science ®Google Scholar
• Iurlo A., Mecucci C., Van Orshoven A. Cytogenetic and clinical investigations in 76 cases with therapy-related leukemia and myelodysplastic syndrome. Cancer Genet. Cytogenet. 1989; 43: 227–241
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J., Philip P. Two different classes of therapy-related and de-novo acute myeloid leukemia?. Cancer Genet. Cytogenet. 1991; 55: 119–124
   PubMed Web of Science ®Google Scholar
• Negrini M., Felix C. A., Martin C. Potential topoisomegase II DNA-binding sites at the breakpoints of t(9;11) chromosome translocation in acute myeloid leukemia. Cancer Res. 1993; 53: 4489–4492
   PubMed Web of Science ®Google Scholar
• Domer P. H., Head D. R., Renganathan N., Raimondi S. C., Yang E., Atlas M. Molecular analysis of 3 cases of MLL/1lq23 secondary acute leukemia and idetification of topoisomerase II consensus-binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4;11). Leukemia 1995; 9: 1305–1312
   PubMed Web of Science ®Google Scholar
• Ford A. M., Ridge S. A., Cabrera M. E. In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature 1993; 363: 358–360
   PubMed Web of Science ®Google Scholar
• Coiffier B., Adeleine P., Viala J. J. Dysmyelopoietic syndromes. A search for prognostic factors in 193 patients. Cancer 1983; 52: 83–90
   PubMed Web of Science ®Google Scholar
• Kerkhofs H., Hermans J., Haak H. L., Leeksma C. H. W. Utility of the FAB classification for myelodysplastic syndromes: Investigation of prognostic factors in 237 cases. Br. J. Haematol. 1987; 65: 73–81
   PubMed Web of Science ®Google Scholar
• Economopoulos T., Stathakis N., Foudoulakis A. Myelodysplastic syndromes: Analysis of 131 cases according to the FAB classification. Eur. J. Haematol. 1987; 38: 338–344
   PubMed Web of Science ®Google Scholar
• Worsley A., Oscier D. G., Stevens J. Prognostic features of chronic myelomonocytic leukaemia: A modified Bournemouth score gives the best prediction of survival. Br. J. Haematol. 1988; 68: 17–21
   PubMed Web of Science ®Google Scholar
• Garcia S., Sanz M. A., Amigo V. Prognostic factors in chronic myelodysplastic syndromes: A multivariate analysis in 107 cases. Am. J. Hematol. 1988; 27: 163–168
   PubMed Web of Science ®Google Scholar
• Riccardi A., Giordano M., Giordano P. Prognostic parameters in myelodysplastic syndromes: A multiple regression analysis. Eur. J. Haematol. 1988; 40: 158–162
   PubMed Web of Science ®Google Scholar
• Sanz G. F., Sanz M. A., Vallepsi T. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74: 395–408
   PubMed Web of Science ®Google Scholar
• Goasguen J. E., Garand R., Bizet M. Prognostic factors of myelodysplastic syndromes—A simplified 3-D scoring system. Leukemia Res. 1990; 14: 255–262
   PubMed Web of Science ®Google Scholar
• Aul C., Gattermann N., Heyll A., Germing U., Derigs G., Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992; 6: 52–59
   PubMed Web of Science ®Google Scholar
• Oguma S., Yoshida Y., Uchino H., Okuma M., Maekawa T., Nomura T. Re-analysis of prognosis in refractory anemia alone, with ring sideroblasts. and with excess of blasts. Int. J. Hematol. 1993; 57: 15–25
   PubMed Web of Science ®Google Scholar
• Tricot G., De Wolf-Peeters C., Vlietinck R., Verwilghen R. L. Bone marrow histology in the myelodysplastic syndromes. II. Prognostic value of ALIP in MDS. Br. J. Haematol. 1984; 58: 217–225
   PubMed Web of Science ®Google Scholar
• Morel P., Hebbar M., Lai J.-L. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 1993; 7: 1315–1323
   PubMed Web of Science ®Google Scholar
• Greenberg P., Fenaux P., Morel P. International workshop consensus risk analysis system for myelodysplastic syndromes (MDS). Blood 1995; 86, (suppl 1), 270a
   Web of Science ®Google Scholar